ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Pharmacology of Anti-Cancer Drugs
This article is part of the Research TopicCellular Pharmacology of Anti-Cancer Immunomodulators: Mechanisms of Sensitivity and Resistance Across the Tumor EcosystemView all 4 articles
A Retrospective Analysis of Outpatient Use of Small-Molecule Targeted Inhibitors for Lymphoma Across Six Regions of China (2016–2022)
Provisionally accepted
- 1Department of Pharmacy, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China
- 2People's Hospital of Quzhou, Quzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective: This study aimed to assess national trends in prescription volumes, drug expenditures, and the pharmacoeconomic rationality of small-molecule targeted inhibitors used for lymphoma treatment among outpatients in China between 2016 and 2022. Methods: Outpatient prescription data for patients diagnosed with lymphoma were obtained from the Hospital Prescription Analysis Cooperative Project database, which includes 77 hospitals distributed across six major regions of China. Annual trends in prescription volume and corresponding drug expenditures were examined. Pharmacoeconomic indicators associated with small-molecule targeted inhibitors were further analyzed to evaluate their cost-effectiveness and utilization patterns. Patient demographic characteristics, regional distribution, and categories of small-molecule targeted inhibitors were also analyzed. Results: Prescription volumes and amounts for small-molecule targeted inhibitors in lymphoma treatment have increased annually. Furthermore, their use is supported by pharmacoeconomic evidence indicating rational and efficient medication utilization. There was a statistically significant increase in total prescriptions (P1 < 0.005) and overall medication expenditures (P2 < 0.005). Conclusion: Between 2016 and 2022, the prescription volume of small-molecule targeted inhibitors for lymphoma increased annually, indicating their expanding clinical use. Since 2020, despite continued growth in prescriptions, drug costs have risen at a slower rate than prescriptions. This reflects that medical insurance negotiation and centralized procurement policies have effectively reduced economic burden without limiting their access to these inhibitors. Pharmacoeconomic indicators also confirm that the use of these drugs has been both reasonable and efficient, allowing for increased drug utilization while reducing financial strain.
Keywords: Lymphoma, Outpatient Prescription Trends, Pharmacoeconomics, small-molecule targeted inhibitors, targeted therapy
Received: 10 Jan 2026; Accepted: 09 Feb 2026.
Copyright: © 2026 Bo, Chen, Chen, 晨, Yang, Hu, Wei, Li and Fu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Liu-Cheng Li
Zhen-Lin Fu
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.